Clinical trial NCT01944709: Phase I/II Study of Vaccination With Antigen Loaded Dendritic Cells (DCs) in Patients With Inoperable Stage III and Stage IV Melanoma
Official title: Phase I/II Study of Vaccination With Antigen Loaded Dendritic Cells (DCs) in Patients With Inoperable Stage III and Stage IV Melanoma
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
PHASE2
Conditions: Melanoma
Keywords: melanoma
dendritic cells
peptide
Melan-A
Lead sponsor: Cantonal Hospital of St. Gallen
Sponsor class: OTHER
First posted: 2013-09-18
Enrollment: 2
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The prognosis of patients with metastatic melanoma is poor and current available treatments are limited. Identification of a number of melanoma-specific tumor antigens that are shared by tumors from different patients, provides attractive targets for immune-based therapies (http://www.bioinfo.org.cn/hptaa/). Different approaches like DNA-/RNA-vaccines, peptide vaccines and dendritic cell (DC) vaccines are under investigation to induce peptide-specific immune responses. In various animal models and in clinical trials it was shown that the most potent induction of anti tumor-specific killer cells was achieved with DC vaccination. DCs are professional antigen presenting cells (APC) that are critical in the initiation of cellular responses in naïve T lymphocytes, in vivo. They are armed with all the molecules needed for the induction of immune responses and have the capacity to migrate into secondary lymphatic organs. In vitro generated dendritic cells are loaded with tumor derived peptides and injected subcutaneously. The concept is to induce or to propagate already existing tumor specific killer T cells.


Eligibility criteria: Inclusion Criteria:

* Histologically confirmed melanoma
* Inoperable Stage III or Stage IV melanoma
* Tumor expression of Melan-A and/or NY-Eso-1 by immunohistochemistry
* Human leukocyte antigen (HLA)-A0201 positivity (flow cytometry and PCR)
* Life expectancy more than three months
* Full recovery from surgery
* Karnofsky scale performance status of 70% or more (App II)
* One prior chemo- or cytokine based therapy is allowed
* Age \> 18 years
* No uncontrolled infections
* Neutrophile count \>1500/ul and thrombocytes \>100 000/ul
* Creatinine \<1.5 of upper normal level
* Adequate liver function with bilirubin \<2 of upper normal level, alanine aminotransferase (ALAT) and aspartate aminotransaminase (ASAT) \< 3 x upper normal level
* Clinically significant (i.e. active) cardiovascular disease: Cardiovascular accident (CVA)/stroke (\< 6 months prior to enrolment), myocardial infarction (\< 6 months prior to enrolment), unstable angina, congestive heart failure or serious cardiac arrythmia requiring medication
* absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
* before patient registration, informed consent must be given according to International Conference on Harmonization (ICH)- Good Clinical Practice (GCP), and national/local regulations

Exclusion Criteria:

* Presently clinically significant heart disease (NYHA Class III or IV)
* Other serious illnesses, eg, serious infections requiring antibiotics, bleeding disorders or uncontrolled peptic ulcer, or seizure or central nervous system disorders
* History of immunodeficiency disease or severe autoimmune disease
* Metastatic disease to the central nervous system
* HIV, hepatitis B virus (HBV), hepatitis C virus (HCV) (test required) or any other severe uncontrolled infection
* Chemotherapy, radiation therapy, or immunotherapy within 4 weeks before study entry
* Concomitant treatment with steroids or antihistamine drugs. Topical or inhalational steroids are permitted
* Participation in any other clinical trial involving another investigational agent within 6 weeks prior to enrollment
* Pregnancy or lactation
* Women of childbearing potential not using a medically acceptable means of contraception
* Lack of availability of the patient for immunological and clinical follow-up assessment.
* Coagulation or bleeding disorders
* Rapidly progressing disease

Primary outcomes:
measure: Toxicity as defined by NCI Common Toxicity Criteria Version 3.0 (App I)
timeFrame: 24 hours
Secondary outcomes:
measure: Response rates in case of measurable disease
timeFrame: 12 weeks, 20 weeks, 28 weeks
Other outcomes:
measure: Peptide specific cellular immunity: Analyses of peptide specific peripheral blood lymphocytes (PBL) by - tetramer method (flow cytometry) - interferon-gamma ELISPOT
timeFrame: 6 weeks, 12 weeks, 20 weeks, 28 weeks
Locations:
city: St.Gallen
country: Switzerland
facility: Cantonal Hospital St.Gallen
Study officials:
affiliation: Cantonal Hospital St. Gallen, Dept. Oncology
name: Silke Gillessen, MD
role: PRINCIPAL_INVESTIGATOR
References: